Attorney Docket No.: 3500.244-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Junker et al.

Application No.: TBA

Group Art Unit: TBA

Filed: June 9, 2000

Examiner: TBA

For: Growth Hormone Crystals

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN 07/961,932 filed January 13, 1993, the benefit of which is claimed under 35 USC 120.

The references are as follows:

- 1. U.S. Patent No. 2,174,862
- 2. European Patent Publication No. 0 355 460
- 3. European Patent Publication No. 0 343 696

- 4. European Patent Publication No. 0 177 478
- 5. European Patent Publication No. 0 216 485
- 6. European Patent Publication No. 0 277 043
- 7. Spitsberg, Anal. Biochem., Vol. 160, No. 2, pp. 489-95 (1987)
- 8. Bell et al., J. Biol. Chem., Vol. 260, No. 14, pp. 8520-8525 (1985)
- 9. International Minerals & Chem. Corp., Chem. Abs. No. 182702t, Vol. 106, No. 22, p. 413 (1987)
- 10. Wilhelmi et al., J. Biol. Chem., Vol. 176, pp. 735-745 (1948)
- J. Clarkson et al., J. Mol. Biol., Vol. 208, pp. 719-721 (1989)
- 12. Noel D. Jones et al., Biotechnology, Vol. 5, pp. 499-500 (1987).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: June 12, 2000

Valeta A. Gregg, Reg. No. 35,127

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

FORM PTO-1449 (Rev. 2-32)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Atty. Docket No. 3500.244-US

Serial No. TBA Applicant Junker et al. Group TBA

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary) Filing Date June 9, 2000

		U.S. PA	TENT DOCUMENTS			, ,	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT	
	2.174.862	10 03 39	Melville Sahyun	167	75	12.3	30.38
							-
						L	
		FOREIGN	PATENT DOCUMENTS	1	•		
	DOCUMENT					TRANSLATION	
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	0 355 460	02/28/90	Europe				
	0 343 696	11/29/89	Europe				
		+	ļ			+	

0 177 478 04/09/86 Europe 0.216.48504/01/87 Europe 0 277 043 08/03/88 Europe

	Spitsberg, Anal. Biochem., Vol. 160, No. 2, pp. 489-95, (1987)
	Bell et al., J. Biol. Chem., Vol. 260, No. 14, pp. 8520-8525 (1985)
	International Minerals & Chem. Corp., Chem. Abs. No. 182702t, Vol. 106,
	No. 22, p. 413 (1987)
	Wilhelmi et al., J. Biol. Chem., Vol. 176, pp. 735-45 (1948)
	J. Clarkson et al., J. Mol. Biol., Vol. 208, pp. 719-721 (1989)
	Noel D. Jones et al., Biotechnology, Vol. 5, pp. 499-500 (1987)
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.